|
1.
|
Barth BM, Shanmugavelandy SS, Kaiser JM, McGovern C, Altinoglu EI, Haakenson JK, Hengst JA, Gilius EL, Knupp SA, Fox TE, Smith JP, Ritty TM, Adair JH, Kester M. PhotoImmunoNanoTherapy Reveals an Anticancer Role for Sphingosine Kinase 2 and Dihydrosphingosine-1-Phosphate. ACS Nano. 2013 Mar 26; 7(3):2132-44.
|
|
|
|
|
2.
|
Fox TE, Young MM, Pedersen MM, Han X, Gardner TW, Kester M. Diabetes Diminishes Phosphatidic Acid in the Retina: A Putative Mediator for Reduced mTOR Signaling and Increased Neuronal Cell Death. Invest Ophthalmol Vis Sci. 2012; 53(11):7257-67.
|
|
|
|
|
3.
|
Kaiser JM, Imai H, Haakenson JK, Brucklacher RM, Fox TE, Shanmugavelandy SS, Unrath KA, Pedersen MM, Dai P, Freeman WM, Bronson SK, Gardner TW, Kester M. Nanoliposomal minocycline for ocular drug delivery. Nanomedicine. 2013 Jan; 9(1):130-40.
|
|
|
|
|
4.
|
Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 2012 Mar; 25(2):259-74.
|
|
|
|
|
5.
|
Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M. Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression. J Biol Chem. 2011 Dec 30; 286(52):44357-66.
|
|
|
|
|
6.
|
Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biol Ther. 2011 Oct 1; 12(7):574-85.
|
|
|
|
|
7.
|
Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, Jarbadan NR, Baab KT, Liao J, Wang HG, Kester M, Desai D, Amin S, Loughran TP, Liu X. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011 Sep 8; 118(10):2793-800.
|
|
|
|
|
8.
|
O'Neill SM, Yun JK, Fox TE, Kester M. Transcriptional regulation of the human neutral ceramidase gene. Arch Biochem Biophys. 2011 Jul; 511(1-2):21-30.
|
|
|
|
|
9.
|
O'Neill SM, Houck KL, Yun JK, Fox TE, Kester M. AP-1 binding transcriptionally regulates human neutral ceramidase. Arch Biochem Biophys. 2011 Jul; 511(1-2):31-9.
|
|
|
|
|
10.
|
Ryland LK, Fox TE, Liu X, Loughran TP, Kester M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther. 2011 Jan 15; 11(2):138-49.
|
|
|
|
|
11.
|
Fox TE, Young MM, Pedersen MM, Giambuzzi-Tussey S, Kester M, Gardner TW. Insulin signaling in retinal neurons is regulated within cholesterol-enriched membrane microdomains. Am J Physiol Endocrinol Metab. 2011 Mar; 300(3):E600-9.
|
|
|
|
|
12.
|
Takahashi Y, Meyerkord CL, Hori T, Runkle K, Fox TE, Kester M, Loughran TP, Wang HG. Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy. 2011 Jan; 7(1):61-73.
|
|
|
|
|
13.
|
Barth BM, Gustafson SJ, Young MM, Fox TE, Shanmugavelandy SS, Kaiser JM, Cabot MC, Kester M, Kuhn TB. Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance. Cancer Biol Ther. 2010 Dec 1; 10(11):1126-36.
|
|
|
|
|
14.
|
Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, Jefferson LS, Kim JK, Bronson SK, Flanagan JM, Kester M. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res. 2011 Mar; 52(3):509-17.
|
|
|
|
|
15.
|
Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR. Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am J Physiol Cell Physiol. 2010 Aug; 299(2):C335-44.
|
|
|
|
|
16.
|
Ganapathi SB, Fox TE, Kester M, Elmslie KS. Ceramide modulates HERG potassium channel gating by translocation into lipid rafts. Am J Physiol Cell Physiol. 2010 Jul; 299(1):C74-86.
|
|
|
|
|
17.
|
Fox TE, Kester M. Therapeutic strategies for diabetes and complications: a role for sphingolipids? Adv Exp Med Biol. 2010; 688:206-16.
|
|
|
|
|
18.
|
Hengst JA, Guilford JM, Fox TE, Wang X, Conroy EJ, Yun JK. Sphingosine kinase 1 localized to the plasma membrane lipid raft microdomain overcomes serum deprivation induced growth inhibition. Arch Biochem Biophys. 2009 Dec; 492(1-2):62-73.
|
|
|
|
|
19.
|
Wijesinghe DS, Allegood JC, Gentile LB, Fox TE, Kester M, Chalfant CE. Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. J Lipid Res. 2010 Mar; 51(3):641-51.
|
|
|
|
|
20.
|
Salli U, Fox TE, Carkaci-Salli N, Sharma A, Robertson GP, Kester M, Vrana KE. Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells Dev. 2009 Jan-Feb; 18(1):55-65.
|
|
|
|
|
21.
|
Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoglu EI, Tabakovic A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett. 2008 Dec; 8(12):4116-21.
|
|
|
|
|
22.
|
Houck KL, Fox TE, Sandirasegarane L, Kester M. Ether-linked diglycerides inhibit vascular smooth muscle cell growth via decreased MAPK and PI3K/Akt signaling. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1657-68.
|
|
|
|
|
23.
|
O'Neill SM, Olympia DK, Fox TE, Brown JT, Stover TC, Houck KL, Wilson R, Waybill P, Kozak M, Levison SW, Weber N, Karavodin LM, Kester M. C(6)-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch-Injured Arteries. Vasc Dis Prev. 2008 Aug 1; 5(3):200-210.
|
|
|
|
|
24.
|
De Cotiis DA, Woll MP, Fox TE, Hill RB, Levenson R, Flanagan JM. Optimized expression and purification of myristoylated human neuronal calcium sensor 1 in E. coli. Protein Expr Purif. 2008 Oct; 61(2):103-12.
|
|
|
|
|
25.
|
Fox TE, Houck KL, O'Neill SM, Nagarajan M, Stover TC, Pomianowski PT, Unal O, Yun JK, Naides SJ, Kester M. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem. 2007 Apr 27; 282(17):12450-7.
|
|
|
|
|
26.
|
Fox TE, Han X, Kelly S, Merrill AH, Martin RE, Anderson RE, Gardner TW, Kester M. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes. 2006 Dec; 55(12):3573-80.
|
|
|
|
|
27.
|
Fox TE, Finnegan CM, Blumenthal R, Kester M. The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci. 2006 May; 63(9):1017-23.
|
|
|
|